PAG
RVPH

Private Advisor Group’s REVIVA PHARMA HLDGS INC RVPH Stock Holding History

Private Advisor Group’s Portfolio RVPH Stock Details RVPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,000
Closed -$191K – 2562
2025
Q1 		$191K Buy
+10,000
New +$314K ﹤0.01% 2113

Other funds holding RVPH

DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Private Advisor Group's RVPH Position: Q2 2025 in Review

Private Advisor Group sold out of REVIVA PHARMA HLDGS INC (RVPH) in Q2 2025, closing a stake of 10,000 shares — an estimated $191K sold.

Private Advisor Group first reported a position in RVPH in Q1 2025 and held it in 1 quarter. The position peaked at $191K in Q1 2025. 46 funds tracked by Wall St. Rank hold RVPH as of Q2 2025.

  • Private Advisor Group reported no remaining REVIVA PHARMA HLDGS INC position as of Q2 2025 after selling out during the quarter.
  • Private Advisor Group sold 10,000 REVIVA PHARMA HLDGS INC shares in Q2 2025, an estimated $191K.
  • Private Advisor Group first reported a position in REVIVA PHARMA HLDGS INC in Q1 2025 and held it in 1 quarter.
  • Private Advisor Group's REVIVA PHARMA HLDGS INC position peaked at $191K in Q1 2025.
  • 46 funds tracked by Wall St. Rank held REVIVA PHARMA HLDGS INC as of Q2 2025.

Based on Private Advisor Group's 13F filing for Q2 2025, filed 11 Aug 2025.